European Code against Cancer 4th Edition: Medical exposures, including hormone therapy, and cancer

Cancer Epidemiology

Volumn 39, Issue , 2015, Pages S107-S119

  Friis, Søren ^a,b   Kesminiene, Ausrele ^c   Espina, Carolina ^c   Auvinen, Anssi ^d,e   Straif, Kurt ^c   Schüz, Joachim ^c  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^e STUK RADIATION AND NUCLEAR SAFETY AUTHORITY   (Finland)

Author keywords

Breast cancer; Cancer, radiation induced; Chemoprevention; Diagnostic X rays; Europe; Hormone replacement therapy; Ionising radiation; Pharmaceuticals; Prevention and control

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; CONTRACEPTIVE AGENT; ESTROGEN; GESTAGEN; HORMONE ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; METFORMIN; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER PREVENTION; CANCER RISK; CARCINOGENICITY; CHEMOPROPHYLAXIS; ENDOMETRIUM CANCER; HORMONE SUBSTITUTION; HUMAN; NEOPLASM; OVARY CANCER; PRIORITY JOURNAL; RADIATION EXPOSURE; TREATMENT DURATION; ADVERSE EFFECTS; EUROPEAN UNION; NEOPLASMS; PRACTICE GUIDELINE; RISK FACTOR; STANDARDS;

EUROPEAN UNION; HORMONE REPLACEMENT THERAPY; HUMANS; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 84942037658     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2015.08.003     Document Type: Article

References (239)

1. [1] Schüz, J., Espina, C., Villain, P., Herrero, R., Leon, M.E., Minozzi, S., et al. European Code against Cancer 4th Edition: 12 ways to reduce your cancer risk. Cancer Epidemiol 39 (2015), S1–S10.
2. [2] International Agency for Research on Cancer, IARC monographs on the evaluation of carcinogenic risks to humans. Combined Estrogen–Progestogen Contraceptives and Combined Estrogen–Progestogen Menopausal therapy, vol. 91, 2007, WHO, Lyon, France.
3. [3] International Agency for Research on Cancer, IARC monographs on the evaluation of carcinogenic risks to humans. A Review of Human Carcinogens, Part A: Pharmaceuticals, vol. 100A, 2012, WHO, Lyon, France.
4. [4] Vera-Badillo, F.E., Al-Mubarak, M., Templeton, A.J., Amir, E., Benefit and harms of new anti-cancer drugs. Curr. Oncol. Rep. 15:3 (2013), 270–275.
5. [5] Jacobs, A., Jacobson-Kram, D., Human carcinogenic risk evaluation, Part III. Assessing cancer hazard and risk in human drug development. Toxicol. Sci. 81:2 (2004), 260–262.
6. [6] Peterson, H.B., Thacker, S.B., Corso, P.S., Marchbanks, P.A., Koplan, J.P., Hormone therapy: making decisions in the face of uncertainty. Arch. Intern. Med. 164:21 (2004), 2308–2312.
7. [7] Burstein, H.J., Prestrud, A.A., Seidenfeld, J., Anderson, H., Buchholz, T.A., Davidson, N.E., et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J. Clin. Oncol. 28:23 (2010), 3784–3796.
8. [8] Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144:5 (2011), 646–674.
9. [9] Umar, A., Dunn, B.K., Greenwald, P., Future directions in cancer prevention. Nat. Rev. Cancer 12:12 (2012), 835–848.
10. [10] Saijo, N., Tamura, T., Nishio, K., Strategy for the development of novel anticancer drugs. Cancer Chemother. Pharmacol. 52:Suppl. (1) (2003), 97–101.
11. [11] Kelloff, G.J., Lippman, S.M., Dannenberg, A.J., Sigman, C.C., Pearce, H.L., Reid, B.J., et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer—a plan to move forward. Clin. Cancer Res. 12:12 (2006), 3661–3697.
12. [12] McColl, N., Auvinen, A., Kesminiene, A., Espina, C., Erdmann, F., de Vries, E., et al. European Code against Cancer 4th Edition: ionising and non-ionising radiation and cancer. Cancer Epidemiol 39 (2015), S93–S100.
13. [13] Royal College of Radiologists, Making the Best Use of a Department of Clinical Radiology. 4th ed., 1998, Royal College of Radiologists, London.
14. [14] Cogliano, V.J., Baan, R., Straif, K., Grosse, Y., Lauby-Secretan, B., El Ghissassi, F., et al. Preventable exposures associated with human cancers. J. Natl. Cancer Inst. 103:24 (2011), 1827–1839.
15. [15] Lauritzen, C., Studd, J., Current Management of the Menopause. 2005, Taylor & Francis, Oxon, UK.
16. [16] Stefanick, M.L., Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am. J. Med. 118:Suppl. (12B) (2005), 64–73.
17. [17] Martindale, Brayfield A., The Complete Drug Reference. 38th ed., 2014, Pharmaceutical Press, Royal Pharmaceutical Society, London.
18. [18] Whitehead, M.I., Campbell, S., Dyer, G., Collins, W.P., Pryse-Davies, J., Ryder, T.A., et al. Progestogen modification of endometrial histology in menopasual women. Br. Med. J. 2:6152 (1978), 1643–1644.
19. [19] Collaborative Group on Hormonal Factors in Breast Cancer, Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:9084 (1997), 1047–1059.
20. [20] Lobo, R.A., Benefits and risks of estrogen replacement therapy. Am. J. Obstet. Gynecol. 173:3 Pt. 2 (1995), 982–989.
21. [21] Rossouw, J.E., Anderson, G.L., Prentice, R.L., Lacroix, A.Z., Kooperberg, C., Stefanick, M.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:3 (2002), 321–333.
22. [22] Manson, J.E., Hsia, J., Johnson, K.C., Rossouw, J.E., Assaf, A.R., Lasser, N.L., et al. Estrogen plus progestin and the risk of coronary heart disease. N. Engl. J. Med. 349:6 (2003), 523–534.
23. [23] Hodis, H.N., Mack, W.J., Lobo, R., Postmenopausal hormone replacement therapy as antiatherosclerotic therapy. Curr. Atheroscler Rep. 4:1 (2002), 52–58.
24. [24] Anderson, G.L., Limacher, M., Assaf, A.R., Bassford, T., Beresford, S.A., Black, H., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291:14 (2004), 1701–1712.
25. [25] Ravdin, P.M., Cronin, K.A., Howlader, N., Berg, C.D., Chlebowski, R.T., Feuer, E.J., et al. The decrease in breast cancer incidence in 2003 in the United States. N. Engl. J. Med. 356:16 (2007), 1670–1674.
26. [26] Katalinic, A., Rawal, R., Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res. Treat. 107:3 (2008), 427–430.
27. [27] Bouchardy, C., Morabia, A., Verkooijen, H.M., Fioretta, G., Wespi, Y., Schafer, P., Remarkable change in age-specific breast cancer incidence in the Swiss canton of Geneva and its possible relation with the use of hormone replacement therapy. BMC Cancer, 6, 2006, 78.
28. [28] Chlebowski, R.T., Kuller, L.H., Prentice, R.L., Stefanick, M.L., Manson, J.E., Gass, M., et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N. Engl. J. Med. 360:6 (2009), 573–587.
29. [29] Marshall, S.F., Clarke, C.A., Deapen, D., Henderson, K., Largent, J., Neuhausen, S.L., et al. Recent breast cancer incidence trends according to hormone therapy use: the California Teachers Study cohort. Breast Cancer Res., 12(1), 2010, R4.
30. [30] Banks, E., Canfell, K., Recent declines in breast cancer incidence: mounting evidence that reduced use of menopausal hormones is largely responsible. Breast Cancer Res., 12(1), 2010, 103.
31. [31] Antoine, C., Ameye, L., Paesmans, M., Rozenberg, S., Systematic review about breast cancer incidence in relation to hormone replacement therapy use. Climacteric 17:2 (2014), 116–132.
32. [32] Gompel, A., Rozenberg, S., Barlow, D.H., The EMAS 2008 update on clinical recommendations on postmenopausal hormone replacement therapy. Maturitas 61:3 (2008), 227–232.
33. [33] Sturdee, D.W., Pines, A., Archer, D.F., Baber, R.J., Barlow, D., Birkhauser, M.H., et al. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 14:3 (2011), 302–320.
34. [34] Nelson, H.D., Walker, M., Zakher, B., Mitchell, J., Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. Preventive Services Task Force recommendations. Ann. Intern. Med. 157:2 (2012), 104–113.
35. [35] Moyer, V.A., Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 158:1 (2013), 47–54.
36. [36] Lacroix, A.Z., Chlebowski, R.T., Manson, J.E., Aragaki, A.K., Johnson, K.C., Martin, L., et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 305:13 (2011), 1305–1314.
37. [37] Schierbeck, L.L., Rejnmark, L., Tofteng, C.L., Stilgren, L., Eiken, P., Mosekilde, L., et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ, 345, 2012, e6409.
38. [38] Boardman, H.M., Hartley, L., Eisinga, A., Main, C., Roqué i Figuls, M., Bonfill Cosp, X., et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst. Rev., 3, 2015 CD002229.
39. [39] Million Women Study Collaborators, Beral, V., Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:9382 (2003), 419–427.
40. [40] Collins, J.A., Blake, J.M., Crosignani, P.G., Breast cancer risk with postmenopausal hormonal treatment. Hum. Reprod. Update 11:6 (2005), 545–560.
41. [41] Greiser, C.M., Greiser, E.M., Doren, M., Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials. Hum. Reprod. Update 11:6 (2005), 561–573.
42. [42] Bakken, K., Fournier, A., Lund, E., Waaseth, M., Dumeaux, V., Clavel-Chapelon, F., et al. Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int. J. Cancer 128:1 (2011), 144–156.
43. [43] Beral, V., Reeves, G., Bull, D., Green, J., Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J. Natl. Cancer Inst. 103:4 (2011), 296–305.
44. [44] Chlebowski, R.T., Manson, J.E., Anderson, G.L., Cauley, J.A., Aragaki, A.K., Stefanick, M.L., et al. Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. J. Natl. Cancer Inst. 105:8 (2013), 526–535.
45. [45] Anderson, G.L., Chlebowski, R.T., Aragaki, A.K., Kuller, L.H., Manson, J.E., Gass, M., et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol. 13:5 (2012), 476–486.
46. [46] Prentice, R.L., Chlebowski, R.T., Stefanick, M.L., Manson, J.E., Langer, R.D., Pettinger, M., et al. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am. J. Epidemiol. 167:12 (2008), 1407–1415.
47. [47] Chlebowski, R.T., Anderson, G.L., Menopausal hormone therapy and breast cancer mortality: clinical implications. Ther. Adv. Drug Saf. 6:2 (2015), 45–56.
48. [48] Anderson, G.L., Chlebowski, R.T., Aragaki, A.K., Kuller, L.H., Manson, J.E., Gass, M., et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol. 13:5 (2012), 476–486.
49. [49] Fournier, A., Mesrine, S., Boutron-Ruault, M.C., Clavel-Chapelon, F., Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?. J. Clin. Oncol. 27:31 (2009), 5138–5143.
50. [50] Reeves, G.K., Beral, V., Green, J., Gathani, T., Bull, D., Hormonal therapy for menopause and breast cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol. 7:11 (2006), 910–918.
51. [51] Prentice, R.L., Chlebowski, R.T., Stefanick, M.L., Manson, J.E., Pettinger, M., Hendrix, S.L., et al. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am. J. Epidemiol. 167:10 (2008), 1207–1216.
52. [52] Crandall, C.J., Aragaki, A.K., Cauley, J.A., McTiernan, A., Manson, J.E., Anderson, G., Chlebowski, R.T., Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women's health initiative clinical trials. Breast Cancer Res. Treat. 132:1 (2012), 275–285.
53. [53] Hou, N., Hong, S., Wang, W., Olopade, O.I., Dignam, J.J., Huo, D., Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density. J. Natl. Cancer Inst. 105:18 (2013), 1365–1372.
54. [54] Narod, S.A., Hormone replacement therapy and the risk of breast cancer. Nat. Rev. Clin. Oncol. 8:11 (2011), 669–676.
55. [55] Santen, R.J., Menopausal hormone therapy and breast cancer. J. Steroid Biochem. Mol. Biol. 142 (2014), 52–61.
56. [56] Chlebowski, R.T., Anderson, G.L., The influence of time from menopause and mammography on hormone therapy-related breast cancer risk assessment. J. Natl. Cancer Inst. 103:4 (2011), 284–285.
57. [57] Fournier, A., Berrino, F., Riboli, E., Avenel, V., Clavel-Chapelon, F., Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int. J. Cancer 114:3 (2005), 448–454.
58. [58] Ewertz, M., Mellemkjaer, L., Poulsen, A.H., Friis, S., Sorensen, H.T., Pedersen, L., et al. Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. Br. J. Cancer 92:7 (2005), 1293–1297.
59. [59] Pesch, B., Ko, Y., Brauch, H., Hamann, U., Harth, V., Rabstein, S., et al. Factors modifying the association between hormone-replacement therapy and breast cancer risk. Eur. J. Epidemiol. 20:8 (2005), 699–711.
60. [60] Chlebowski, R.T., Anderson, G.L., Gass, M., Lane, D.S., Aragaki, A.K., Kuller, L.H., et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304:15 (2010), 1684–1692.
61. [61] Tsilidis, K.K., Allen, N.E., Key, T.J., Dossus, L., Kaaks, R., Bakken, K., et al. Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition. Cancer Causes Control 22:8 (2011), 1075–1084.
62. [62] Manson, J.E., Chlebowski, R.T., Stefanick, M.L., Aragaki, A.K., Rossouw, J.E., Prentice, R.L., et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 310:13 (2013), 1353–1368.
63. [63] Furness, S., Roberts, H., Marjoribanks, J., Lethaby, A., Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst. Rev., 8, 2012, CD000402.
64. [64] Grady, D., Gebretsadik, T., Kerlikowske, K., Ernster, V., Petitti, D., Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet. Gynecol. 85:2 (1995), 304–313.
65. [65] Beral, V., Bull, D., Reeves, G., Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365:9470 (2005), 1543–1551.
66. [66] Allen, N.E., Tsilidis, K.K., Key, T.J., Dossus, L., Kaaks, R., Lund, E., et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition. Am. J. Epidemiol. 172:12 (2010), 1394–1403.
67. [67] Phipps, A.I., Doherty, J.A., Voigt, L.F., Hill, D.A., Beresford, S.A., Rossing, M.A., et al. Long-term use of continuous-combined estrogen-progestin hormone therapy and risk of endometrial cancer. Cancer Causes Control 22:12 (2011), 1639–1646.
68. [68] Trabert, B., Wentzensen, N., Yang, H.P., Sherman, M.E., Hollenbeck, A.R., Park, Y., Brinton, L.A., Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk?. Int. J. Cancer 132:2 (2013), 417–426.
69. [69] Brinton, L.A., Felix, A.S., Menopausal hormone therapy and risk of endometrial cancer. J. Steroid Biochem. Mol. Biol. 142 (2014), 83–89.
70. [70] Pearce, C.L., Chung, K., Pike, M.C., Wu, A.H., Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer 115:3 (2009), 531–539.
71. [71] Tsilidis, K.K., Allen, N.E., Key, T.J., Dossus, L., Kaaks, R., Bakken, K., et al. Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition. Cancer Causes Control 22:8 (2011), 1075–1084.
72. [72] Mørch, L.S., Løkkegaard, E., Andreasen, A.H., Kjær, S.K., Lidegaard, O., Hormone therapy and different ovarian cancers: a national cohort study. Am. J. Epidemiol. 175:12 (2012), 1234–1242.
73. [73] Beral, V., Gaitskell, K., Hermon, C., Moser, K., Reeves, G., Peto, R., the Collaborative Group on Epidemiological Studies of Ovarian Cancer, Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 385:9980 (2015), 1835–1842.
74. [74] Beral, V., Bull, D., Green, J., Reeves, G., Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369:9574 (2007), 1703–1710.
75. [75] Gompel, A., Burger, H., A Commentary on a recent update of the ovarian cancer risk attributable to menopausal hormone therapy. Climacteric 18:3 (2015), 376–378.
76. [76] Grodstein, F., Newcomb, P.A., Stampfer, M.J., Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am. J. Med. 106:5 (1999), 574–582.
77. [77] Nanda, K., Bastian, L.A., Hasselblad, V., Simel, D.L., Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet. Gynecol. 93:5 Pt. 2 (1999), 880–888.
78. [78] Barnes, E.L., Long, M.D., Colorectal cancer in women: hormone replacement therapy and chemoprevention. Climacteric 15:3 (2012), 250–255.
79. [79] Lin, K.J., Cheung, W.Y., Lai, J.Y., Giovannucci, E.L., The effect of estrogen vs. combined estrogen-progestogen therapy on the risk of colorectal cancer. Int. J. Cancer 130:2 (2012), 419–430.
80. [80] Green, J., Czanner, G., Reeves, G., Watson, J., Wise, L., Roddam, A., Beral, V., Menopausal hormone therapy and risk of gastrointestinal cancer: nested case-control study within a prospective cohort, and meta-analysis. Int. J. Cancer 130:10 (2012), 2387–2396.
81. [81] Johnson, C.M., Wei, C., Ensor, J.E., Smolenski, D.J., Amos, C.I., Levin, B., Berry, D.A., Meta-analyses of colorectal cancer risk factors. Cancer Causes Control 24:6 (2013), 1207–1222.
82. [82] Wahab, M., Al-Azzawi, F., Meningioma and hormonal influences. Climacteric 6:4 (2003), 285–292.
83. [83] Blitshteyn, S., Crook, J.E., Jaeckle, K.A., Is there an association between meningioma and hormone replacement therapy?. J. Clin. Oncol. 26:2 (2008), 279–282.
84. [84] Benson, V.S., Pirie, K., Green, J., Bull, D., Casabonne, D., Reeves, G.K., Beral, V., Hormone replacement therapy and incidence of central nervous system tumours in the Million Women Study. Int. J. Cancer 127:7 (2010), 1692–1698.
85. [85] Andersen, L., Friis, S., Hallas, J., Ravn, P., Schroder, H.D., Gaist, D., Hormone replacement therapy increases the risk of cranial meningioma. Eur. J. Cancer 49:15 (2013), 3303–3310.
86. [86] Fan, Z.X., Shen, J., Wu, Y.Y., Yu, H., Zhu, Y., Zhan, R.Y., Hormone replacement therapy and risk of meningioma in women: a meta-analysis. Cancer Causes Control 24:8 (2013), 1517–1525.
87. [87] Camargo, M.C., Goto, Y., Zabaleta, J., Morgan, D.R., Correa, P., Rabkin, C.S., Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis. Cancer Epidemiol. Biomarkers Prev. 21:1 (2012), 20–38.
88. [88] Lagergren, K., Lagergren, J., Brusselaers, N., Hormone replacement therapy and oral contraceptives and risk of oesophageal adenocarcinoma: a systematic review and meta-analysis. Int. J. Cancer 135:9 (2014), 2183–2190.
89. [89] Yao, Y., Gu, X., Zhu, J., Yuan, D., Song, Y., Hormone replacement therapy in females can decrease the risk of lung cancer: a meta-analysis. PLoS One, 8(8), 2013, e71236.
90. [90] Chlebowski, R.T., Anderson, G.L., Manson, J.E., Schwartz, A.G., Wakelee, H., Gass, M., et al. Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. J. Natl. Cancer Inst. 102:18 (2010), 1413–1421.
91. [91] Chlebowski, R.T., Schwartz, A.G., Wakelee, H., Anderson, G.L., Stefanick, M.L., Manson, J.E., et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 374:9697 (2009), 1243–1251.
92. [92] Grindlay, K., Burns, B., Grossman, D., Prescription requirements and over-the-counter access to oral contraceptives: a global review. Contraception 88:1 (2013), 91–96.
93. [93] WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC Classification and DDD Assignment. 2013, WHO, Oslo.
94. [94] Spencer, A.L., Bonnema, R., McNamara, M.C., Helping women choose appropriate hormonal contraception: update on risks, benefits, and indications. Am. J. Med. 122:6 (2009), 497–506.
95. [95] McKenzie, B.E., Guidelines and requirements for the evaluation of contraceptive steroids. Toxicol. Pathol. 17:2 (1989), 377–384.
96. [96] Cibula, D., Gompel, A., Mueck, A.O., La Vecchia, C., Hannaford, P.C., Skouby, S.O., et al. Hormonal contraception and risk of cancer. Hum. Reprod. Update 16:6 (2010), 631–650.
97. [97] Jacobs, A.C., Hatfield, K.P., History of chronic toxicity and animal carcinogenicity studies for pharmaceuticals. Vet. Pathol. 50:2 (2013), 324–333.
98. [98] Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347:9017 (1996), 1713–1727.
99. [99] Kahlenborn, C., Modugno, F., Potter, D.M., Severs, W.B., Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. Mayo Clin. Proc. 81:10 (2006), 1290–1302.
100. [100] Zhu, H., Lei, X., Feng, J., Wang, Y., Oral contraceptive use and risk of breast cancer: a meta-analysis of prospective cohort studies. Eur. J. Contracept. Reprod. Health Care 17:6 (2012), 402–414.
101. [101] Appleby, P., Beral, V., Berrington de González, A., Colin, D., Franceschi, S., Goodhill, A., et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 370:9599 (2007), 1609–1621.
102. [102] Maheshwari, S., Sarraj, A., Kramer, J., El-Serag, H.B., Oral contraception and the risk of hepatocellular carcinoma. J. Hepatol. 47:4 (2007), 506–513.
103. [103] Stegeman, B.H., de Bastos, M., Rosendaal, F.R., van Hylckama Vlieg, A., Helmerhorst, F.M., Stijnen, T., Dekkers, O.M., Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ, 347, 2013, f5298.
104. [104] Havrilesky, L.J., Moorman, P.G., Lowery, W.J., Gierisch, J.M., Coeytaux, R.R., Urrutia, R.P., et al. Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet. Gynecol. 122:1 (2013), 139–147.
105. [105] Mueck, A.O., Seeger, H., Rabe, T., Hormonal contraception and risk of endometrial cancer: a systematic review. Endocr. Relat. Cancer 17:4 (2010), R263–R271.
106. [106] Grimes, D.A., Economy, K.E., Primary prevention of gynecologic cancers. Am. J. Obstet. Gynecol. 172:1 Pt. 1 (1995), 227–235.
107. [107] Schlesselman, J.J., Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner's guide to meta-analysis. Hum. Reprod. 12:9 (1997), 1851–1863.
108. [108] Fernandez, E., La Vecchia, C., Balducci, A., Chatenoud, L., Franceschi, S., Negri, E., Oral contraceptives and colorectal cancer risk: a meta-analysis. Br. J. Cancer 84:5 (2001), 722–727.
109. [109] Karagas, M.R., Stukel, T.A., Dykes, J., Miglionico, J., Greene, M.A., Carey, M., et al. A pooled analysis of 10 case-control studies of melanoma and oral contraceptive use. Br. J. Cancer 86:7 (2002), 1085–1092.
110. [110] Smith, J.S., Green, J., Berrington de González, A., Appleby, P., Peto, J., Plummer, M., et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 361:9364 (2003), 1159–1167.
111. [111] Bosetti, C., Bravi, F., Negri, E., La Vecchia, C., Oral contraceptives and colorectal cancer risk: a systematic review and meta-analysis. Hum. Reprod. Update 15:5 (2009), 489–498.
112. [112] Iodice, S., Barile, M., Rotmensz, N., Feroce, I., Bonanni, B., Radice, P., et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur. J. Cancer 46:12 (2010), 2275–2284.
113. [113] Blonski, W., Kotlyar, D.S., Forde, K.A., Non-viral causes of hepatocellular carcinoma. World J. Gastroenterol. 16:29 (2010), 3603–3615.
114. [114] Cibula, D., Zikan, M., Dusek, L., Majek, O., Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev. Anticancer Ther. 11:8 (2011), 1197–1207.
115. [115] Gandini, S., Iodice, S., Koomen, E., Di Pietro, A., Sera, F., Caini, S., Hormonal and reproductive factors in relation to melanoma in women: current review and meta-analysis. Eur. J. Cancer 47:17 (2011), 2607–2617.
116. [116] Kane, E.V., Roman, E., Becker, N., Bernstein, L., Boffetta, P., Bracci, P.M., et al. Menstrual and reproductive factors, and hormonal contraception use: associations with non-Hodgkin lymphoma in a pooled analysis of InterLymph case-control studies. Ann. Oncol. 23:9 (2012), 2362–2374.
117. [117] Moorman, P.G., Havrilesky, L.J., Gierisch, J.M., Coeytaux, R.R., Lowery, W.J., Peragallo, U.R., et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J. Clin. Oncol. 31:33 (2013), 4188–4198.
118. [118] Gierisch, J.M., Coeytaux, R.R., Urrutia, R.P., Havrilesky, L.J., Moorman, P.G., Lowery, W.J., et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol. Biomarkers Prev. 22:11 (2013), 1931–1943.
119. [119] Wu, W., Yin, Z.H., Guan, P., Ren, Y.W., Zhou, B.S., Association of oral contraceptives use and lung cancer risk among women: an updated meta-analysis based on cohort and case-control studies. Asian Pac. J. Cancer Prev. 15:3 (2014), 1205–1210.
120. [120] Liu, H., Wang, X.C., Hu, G.H., Huang, T.B., Xu, Y.F., Oral contraceptive use and kidney cancer risk among women: evidence from a meta-analysis. Int. J. Clin. Exp. Med. 7:11 (2014), 3954–3963.
121. [121] Cuzick, J., DeCensi, A., Arun, B., Brown, P.H., Castiglione, M., Dunn, B., et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 12:5 (2011), 496–503.
122. [122] Nelson, H.D., Smith, M.E., Griffin, J.C., Fu, R., Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 158:8 (2013), 604–614.
123. [123] Olsen, J.H., Møller, T., Anderson, H., Langmark, F., Sankila, R., Tryggvadottir, L., et al. Lifelong cancer incidence in 47,697 patients treated for childhood cancer in the Nordic countries. J. Natl. Cancer Inst. 101:11 (2009), 806–813.
124. [124] Travis, L.B., Demark, W.W., Allan, J.M., Wood, M.E., Ng, A.K., Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat. Rev. Clin. Oncol. 10:5 (2013), 289–301.
125. [125] Wood, M.E., Vogel, V., Ng, A., Foxhall, L., Goodwin, P., Travis, L.B., Second malignant neoplasms: assessment and strategies for risk reduction. J. Clin. Oncol. 30:30 (2012), 3734–3745.
126. [126] Grosse, Y., Baan, R., Straif, K., Secretan, B., El Ghissassi, F., Bouvard, V., et al. A review of human carcinogens-Part A: pharmaceuticals. Lancet Oncol. 10:1 (2009), 13–14.
127. [127] Godley, L.A., Larson, R.A., Therapy-related myeloid leukemia. Semin. Oncol. 35:4 (2008), 418–429.
128. [128] Sill, H., Olipitz, W., Zebisch, A., Schulz, E., Wolfler, A., Therapy-related myeloid neoplasms: pathobiology and clinical characteristics. Br. J. Pharmacol. 162:4 (2011), 792–805.
129. [129] Vineis, P., Pirastu, R., Aromatic amines and cancer. Cancer Causes Control 8:3 (1997), 346–355.
130. [130] Swerdlow, A.J., Higgins, C.D., Smith, P., Cunningham, D., Hancock, B.W., Horwich, A., et al. Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. J. Clin. Oncol. 29:31 (2011), 4096–4104.
131. [131] Travis, L.B., Demark, W.W., Allan, J.M., Wood, M.E., Ng, A.K., Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat. Rev. Clin. Oncol. 10:5 (2013), 289–301.
132. [132] Maltzman, J.S., Koretzky, G.A., Azathioprine old drug, new actions. J. Clin. Invest. 111:8 (2003), 1122–1124.
133. [133] Forsythe, P., Paterson, S., Ciclosporin 10 years on: indications and efficacy. Vet. Rec. 174:Suppl. (2) (2014), 13–21.
134. [134] Rama, I., Grinyo, J.M., Malignancy after renal transplantation: the role of immunosuppression. Nat. Rev. Nephrol. 6:9 (2010), 511–519.
135. [135] Corthay, A., Does the immune system naturally protect against cancer?. Front. Immunol., 5, 2014, 197.
136. [136] Euvrard, S., Kanitakis, J., Claudy, A., Skin cancers after organ transplantation. N. Engl. J. Med. 348:17 (2003), 1681–1691.
137. [137] Gutierrez-Dalmau, A., Campistol, J.M., Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs 67:8 (2007), 1167–1198.
138. [138] Engels, E.A., Pfeiffer, R.M., Fraumeni, J.F. Jr., Kasiske, B.L., Israni, A.K., Snyder, J.J., et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 306:17 (2011), 1891–1901.
139. [139] Schmeiser, H.H., Kucab, J.E., Arlt, V.M., Phillips, D.H., Hollstein, M., Gluhovschi, G., et al. Evidence of exposure to aristolochic acid in patients with urothelial cancer from a Balkan endemic nephropathy region of Romania. Environ. Mol. Mutagen 53:8 (2012), 636–641.
140. [140] Chen, C.H., Dickman, K.G., Moriya, M., Zavadil, J., Sidorenko, V.S., Edwards, K.L.J.T., et al. Aristolochic acid-associated urothelial cancer in Taiwan. Proc. Natl. Acad. Sci. U. S. A. 109:21 (2012), 8241–8246.
141. [141] Schmeiser, H.H., Stiborova, M., Arlt, V.M., Chemical and molecular basis of the carcinogenicity of Aristolochia plants. Curr. Opin. Drug Discov. Dev. 12:1 (2009), 141–148.
142. [142] Hollstein, M., Moriya, M., Grollman, A.P., Olivier, M., Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid. Mutat. Res. 753:1 (2013), 41–49.
143. [143] Krell, D., Stebbing, J., Aristolochia the malignant truth. Lancet Oncol. 14:1 (2013), 25–26.
144. [144] McNeely, W., Goa, K.L., 5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo. Drugs 56:4 (1998), 667–690.
145. [145] Archier, E., Devaux, S., Castela, E., Gallini, A., Aubin, F., Le, M.M., et al. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J. Eur. Acad. Dermatol. Venereol. 26:Suppl. (3) (2012), 22–31.
146. [146] Friedman, G.D., Asgari, M.M., Warton, E.M., Chan, J., Habel, L.A., Antihypertensive drugs and lip cancer in non-Hispanic whites. Arch. Intern. Med. 172:16 (2012), 1246–1251.
147. [147] Sporn, M.B., Dunlop, N.M., Newton, D.L., Smith, J.M., Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed. Proc. 35:6 (1976), 1332–1338.
148. [148] Patterson, S.L., Colbert, M.K., Hawk, E., Cancer chemoprevention: successes and failures. Clin. Chem. 59:1 (2013), 94–101.
149. [149] Pinkerton, J.V., Thomas, S., Use of SERMs for treatment in postmenopausal women. J. Steroid Biochem. Mol. Biol. 142C (2014), 142–154.
150. [150] Sainsbury, R., The development of endocrine therapy for women with breast cancer. Cancer Treat. Rev. 39:5 (2013), 507–517.
151. [151] Visvanathan, K., Hurley, P., Bantug, E., Brown, P., Col, N.F., Cuzick, J., et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 31:23 (2013), 2942–2962.
152. [152] Cuzick, J., Sestak, I., Bonanni, B., Costantino, J.P., Cummings, S., DeCensi, A., et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 381:9880 (2013), 1827–1834.
153. [153] Goss, P.E., Ingle, J.N., Ales-Martinez, J.E., Cheung, A.M., Chlebowski, R.T., Wactawski-Wende, J., et al. Exemestane for breast-cancer prevention in postmenopausal women. N. Engl. J. Med. 364:25 (2011), 2381–2391.
154. [154] Cuzick, J., Sestak, I., Forbes, J.F., Dowsett, M., Knox, J., Cawthorn, S., et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 383:9922 (2014), 1041–1048.
155. [155] Cuzick, J., Otto, F., Baron, J.A., Brown, P.H., Burn, J., Greenwald, P., et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 10:5 (2009), 501–507.
156. [156] Chan, A.T., Arber, N., Burn, J., Chia, W.K., Elwood, P., Hull, M.A., et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev. Res. (Phila) 5:2 (2012), 164–178.
157. [157] Friis, S., Riis, A.H., Erichsen, R., Baron, J.A., Sørensen, H.T., Low-dose aspirin or nonsteroidal anti-inflammatory drug use and colorectal cancer risk: A population-based, case-control study. Ann. Intern. Med. 163:5 (2015), 347–355.
158. [158] Cuzick, J., Thorat, M.A., Bosetti, C., Brown, P.H., Burn, J., Cook, N.R., et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann. Oncol. 1 (2015), 47–57.
159. [159] Cook, N.R., Lee, I.M., Zhang, S.M., Moorthy, M.V., Buring, J.E., Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann. Intern. Med. 159:2 (2013), 77–85.
160. [160] Rothwell, P.M., Wilson, M., Elwin, C.E., Norrving, B., Algra, A., Warlow, C.P., Meade, T.W., Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376:9754 (2010), 1741–1750.
161. [161] Rothwell, P.M., Price, J.F., Fowkes, F.G., Zanchetti, A., Roncaglioni, M.C., Tognoni, G., et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379:9826 (2012), 1602–1612.
162. [162] Baron, J.A., Sandler, R.S., Bresalier, R.S., Quan, H., Riddell, R., Lanas, A., et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 131:6 (2006), 1674–1682.
163. [163] Bertagnolli, M.M., Eagle, C.J., Zauber, A.G., Redston, M., Solomon, S.D., Kim, K., et al. Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 355:9 (2006), 873–884.
164. [164] Arber, N., Eagle, C.J., Spicak, J., Racz, I., Dite, P., Hajer, J., et al. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 355:9 (2006), 885–895.
165. [165] Cole, B.F., Logan, R.F., Halabi, S., Benamouzig, R., Sandler, R.S., Grainge, M.J., et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J. Natl. Cancer Inst. 101:4 (2009), 256–266.
166. [166] Ishikawa, H., Mutoh, M., Suzuki, S., Tokudome, S., Saida, Y., Abe, T., et al. The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial. Gut 63:11 (2014), 1755–1759.
167. [167] Nugent, K.P., Farmer, K.C., Spigelman, A.D., Williams, C.B., Phillips, R.K., Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br. J. Surg. 80:12 (1993), 1618–1619.
168. [168] Burn, J., Gerdes, A.M., Macrae, F., Mecklin, J.P., Moeslein, G., Olschwang, S., et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 4:5 (2011), 655–665.
169. [169] Yang, P., Zhou, Y., Chen, B., Wan, H.W., Jia, G.Q., Bai, H.L., Wu, X.T., Aspirin use and the risk of gastric cancer: a meta-analysis. Dig. Dis. Sci. 55:6 (2010), 1533–1539.
170. [170] Sun, L., Yu, S., Meta-analysis non-steroidal anti-inflammatory drug use and the risk of esophageal squamous cell carcinoma. Dis. Esophagus 24:8 (2011), 544–549.
171. [171] Ye, X., Fu, J., Yang, Y., Gao, Y., Liu, L., Chen, S., Frequency-risk and duration-risk relationships between aspirin use and gastric cancer: a systematic review and meta-analysis. PLoS One, 8(7), 2013, e71522.
172. [172] Sivarasan, N., Smith, G., Role of aspirin in chemoprevention of esophageal adenocarcinoma: a meta-analysis. J. Dig. Dis. 14:5 (2013), 222–230.
173. [173] Takkouche, B., Regueira-Mendez, C., Etminan, M., Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J. Natl. Cancer Inst. 100:20 (2008), 1439–1447.
174. [174] Zhao, Y.S., Zhu, S., Li, X.W., Wang, F., Hu, F.L., Li, D.D., et al. Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis. Breast Cancer Res. Treat. 117:1 (2009), 141–150.
175. [175] Luo, T., Yan, H.M., He, P., Luo, Y., Yang, Y.F., Zheng, H., Aspirin use and breast cancer risk: a meta-analysis. Breast Cancer Res. Treat. 131:2 (2012), 581–587.
176. [176] Oh, S.W., Myung, S.K., Park, J.Y., Lee, C.M., Kwon, H.T., Aspirin use and risk for lung cancer: a meta-analysis. Ann. Oncol. 22:11 (2011), 2456–2465.
177. [177] Xu, J., Yin, Z., Gao, W., Liu, L., Wang, R., Huang, P., et al. Meta-analysis on the association between nonsteroidal anti-inflammatory drug use and lung cancer risk. Clin. Lung Cancer 13:1 (2012), 44–51.
178. [178] Neill, A.S., Nagle, C.M., Protani, M.M., Obermair, A., Spurdle, A.B., Webb, P.M., Aspirin, nonsteroidal anti-inflammatory drugs, paracetamol and risk of endometrial cancer: a case-control study, systematic review and meta-analysis. Int. J. Cancer 132:5 (2013), 1146–1155.
179. [179] Lo-Ciganic, W.H., Zgibor, J.C., Bunker, C.H., Moysich, K.B., Edwards, R.P., Ness, R.B., Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or acetaminophen and risk of ovarian cancer. Epidemiology 23:2 (2012), 311–319.
180. [180] Baandrup, L., Faber, M.T., Christensen, J., Jensen, A., Andersen, K.K., Friis, S., Kjaer, S.K., Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies. Acta Obstet. Gynecol. Scand. 92:3 (2013), 245–255.
181. [181] Huang, T.B., Yan, Y., Guo, Z.F., Zhang, X.L., Liu, H., Geng, J., et al. Aspirin use and the risk of prostate cancer: a meta-analysis of 24 epidemiologic studies. Int. Urol. Nephrol., 2014.
182. [182] Liu, Y., Chen, J.Q., Xie, L., Wang, J., Li, T., He, Y., et al. Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis. BMC Med., 12, 2014, 55.
183. [183] Fischer, S.M., Hawk, E.T., Lubet, R.A., Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prev. Res. (Phila) 4:11 (2011), 1728–1735.
184. [184] Thun, M.J., Jacobs, E.J., Patrono, C., The role of aspirin in cancer prevention. Nat. Rev. Clin. Oncol. 9:5 (2012), 259–267.
185. [185] Stolfi, C., De Simone, V., Pallone, V.F., Monteleone, F.G., Mechanisms of action of non-steroidal anti-inflammatory drugs (NSAIDs) and mesalazine in the chemoprevention of colorectal cancer. Int. J. Mol. Sci. 14:9 (2013), 17972–17985.
186. [186] Bhala, N., Emberson, J., Merhi, A., Abramson, S., Arber, N., Baron, J.A., et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382:9894 (2013), 769–779.
187. [187] Varas-Lorenzo, C., Riera-Guardia, N., Calingaert, B., Castellsague, J., Salvo, F., Nicotra, F., et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol. Drug Saf. 22:6 (2013), 559–570.
188. [188] Thorat, M.A., Cuzick, J., Role of aspirin in cancer prevention. Curr. Oncol. Rep. 15:6 (2013), 533–540.
189. [189] Steinhubl, S.R., Bhatt, D.L., Brennan, D.M., Montalescot, G., Hankey, G.J., Eikelboom, J.W., et al. Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann. Intern. Med. 150:6 (2009), 379–386.
190. [190] Gazzerro, P., Proto, M.C., Gangemi, G., Malfitano, A.M., Ciaglia, E., Pisanti, S., et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol. Rev. 64:1 (2012), 102–146.
191. [191] Osmak, M., Statins and cancer: current and future prospects. Cancer Lett. 324:1 (2012), 1–12.
192. [192] Lochhead, P., Chan, A.T., Statins and colorectal cancer. Clin. Gastroenterol. Hepatol. 11:2 (2013), 109–118.
193. [193] Corcos, L., Le Jossic-Corcos, C., Statins perspectives in cancer therapeutics. Dig. Liver Dis. 45:10 (2013), 795–802.
194. [194] Boudreau, D.M., Yu, O., Johnson, J., Statin use and cancer risk: a comprehensive review. Expert Opin. Drug Saf. 9:4 (2010), 603–621.
195. [195] Bonovas, S., Filioussi, K., Sitaras, N.M., Statin use and the risk of prostate cancer: a metaanalysis of 6 randomized clinical trials and 13 observational studies. Int. J. Cancer 123:4 (2008), 899–904.
196. [196] Wu, X.D., Zeng, K., Xue, F.Q., Chen, J.H., Chen, Y.Q., Statins are associated with reduced risk of gastric cancer: a meta-analysis. Eur. J. Clin. Pharmacol. 69:10 (2013), 1855–1860.
197. [197] Singh, P.P., Singh, S., Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis. Ann. Oncol. 24:7 (2013), 1721–1730.
198. [198] Singh, S., Singh, P.P., Singh, A.G., Murad, M.H., Sanchez, W., Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 144:2 (2013), 323–332.
199. [199] Singh, S., Singh, A.G., Singh, P.P., Murad, M.H., Iyer, P.G., Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 11:6 (2013), 620–629.
200. [200] Bonovas, S., Nikolopoulos, G., Sitaras, N.M., Statins and reduced risk of hepatocellular carcinoma in patients with hepatitis C virus infection: further evidence is warranted. J. Clin. Oncol., 31(32), 2013, 4160.
201. [201] Pradelli, D., Soranna, D., Scotti, L., Zambon, A., Catapano, A., Mancia, G., et al. Statins and primary liver cancer: a meta-analysis of observational studies. Eur. J. Cancer Prev. 22:3 (2013), 229–234.
202. [202] Lytras, T., Nikolopoulos, G., Bonovas, S., Statins and the risk of colorectal cancer: an updated systematic review and meta-analysis of 40 studies. World J. Gastroenterol. 20:7 (2014), 1858–1870.
203. [203] Liu, Y., Tang, W., Wang, J., Xie, L., Li, T., He, Y., et al. Association between statin use and colorectal cancer risk: a meta-analysis of 42 studies. Cancer Causes Control 25:2 (2014), 237–249.
204. [204] Liu, Y., Qin, A., Li, T., Qin, X., Li, S., Effect of statin on risk of gynecologic cancers: a meta-analysis of observational studies and randomized controlled trials. Gynecol. Oncol. 133:3 (2014), 647–655.
205. [205] Carrat, F., Statin and aspirin for prevention of hepatocellular carcinoma: what are the levels of evidence?. Clin. Res. Hepatol. Gastroenterol. 38:1 (2014), 9–11.
206. [206] Zhang, Z.J., Zheng, Z.J., Kan, H., Song, Y., Cui, W., Zhao, G., Kip, K.E., Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care 34:10 (2011), 2323–2328.
207. [207] Stevens, R.J., Ali, R., Bankhead, C.R., Bethel, M.A., Cairns, B.J., Camisasca, R.P., et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia 55:10 (2012), 2593–2603.
208. [208] Kourelis, T.V., Siegel, R.D., Metformin and cancer: new applications for an old drug. Med. Oncol. 29:2 (2012), 1314–1327.
209. [209] Col, N.F., Ochs, L., Springmann, V., Aragaki, A.K., Chlebowski, R.T., Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Res. Treat. 135:3 (2012), 639–646.
210. [210] Zhang, Z.J., Zheng, Z.J., Shi, R., Su, Q., Jiang, Q., Kip, K.E., Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 97:7 (2012), 2347–2353.
211. [211] Thakkar, B., Aronis, K.N., Vamvini, M.T., Shields, K., Mantzoros, C.S., Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. Metabolism 62:7 (2013), 922–934.
212. [212] Rizos, C.V., Elisaf, M.S., Metformin and cancer. Eur. J. Pharmacol. 705:1–3 (2013), 96–108.
213. [213] Zhang, P., Li, H., Tan, X., Chen, L., Wang, S., Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol. 37:3 (2013), 207–218.
214. [214] Zhang, Z.J., Bi, Y., Li, S., Zhang, Q., Zhao, G., Guo, Y., Song, Q., Reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and meta-analysis. Am. J. Epidemiol. 180:1 (2014), 11–14.
215. [215] Kasznicki, J., Sliwinska, A., Drzewoski, J., Metformin in cancer prevention and therapy. Ann. Transl. Med., 2(6), 2014, 57.
216. [216] Gandini, S., Puntoni, M., Heckman-Stoddard, B.M., Dunn, B.K., Ford, L., DeCensi, A., Szabo, E., Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev. Res. (Phila) 7:9 (2014), 867–885.
217. [217] Onitilo, A.A., Engel, J.M., Glurich, I., Stankowski, R.V., Williams, G.M., Doi, S.A., Diabetes and cancer II: role of diabetes medications and influence of shared risk factors. Cancer Causes Control 23:7 (2012), 991–1008.
218. [218] McFarland, M.S., Cripps, R., Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs. Pharmacotherapy 30:11 (2010), 1159–1178.
219. [219] Thompson, I.M., Goodman, P.J., Tangen, C.M., Lucia, M.S., Miller, G.J., Ford, L.G., et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349:3 (2003), 215–224.
220. [220] Andriole, G.L., Bostwick, D.G., Brawley, O.W., Gomella, L.G., Marberger, M., Montorsi, F., et al. Effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med. 362:13 (2010), 1192–1202.
221. [221] Azzouni, F., Mohler, J., Role of 5alpha-reductase inhibitors in prostate cancer prevention and treatment. Urology 79:6 (2012), 1197–1205.
222. [222] Thompson, I.M. Jr., Goodman, P.J., Tangen, C.M., Parnes, H.L., Minasian, L.M., Godley, P.A., et al. Long-term survival of participants in the prostate cancer prevention trial. N. Engl. J. Med. 369:7 (2013), 603–610.
223. [223] Klein, E.A., Thompson, I.M., Chemoprevention of prostate cancer: an updated view. World J. Urol. 30:2 (2012), 189–194.
224. [224] Sandhu, G.S., Nepple, K.G., Tanagho, Y.S., Andriole, G.L., Prostate cancer chemoprevention. Semin. Oncol. 40:3 (2013), 276–285.
225. [225] International Agency for Research on Cancer, IARC monographs on the evaluation of carcinogenic risks to humans. A Review of Human Carcinogens, Part D: Radiation, vol. 100D, 2012, WHO, Lyon, France.
226. [226] United Nations Scientific Committee on the Effects of Atomic Radiation, UNSCEAR 2006 Report: Sources and Effects of Ionizing Radiation. Report to the General Assembly, vol. 1, with Scientific Annexes A and B, 2008, United Nations, New York.
227. [227] International Commission on Radiological Protection (ICRP), ICRP Publication 103: Recommendations of the International Commission for Radiation Protection. 2012, International Commission on Radiological Protection.
228. [228] United Nations Scientific Committee on the Effects of Atomic Radiation, UNSCEAR 2000 Report: Sources and Effects of Ionizing Radiation. Report to the General Assembly, vol. 1: Effects, 2000, United Nations, New York.
229. [229] United Nations Scientific Committee on the Effects of Atomic Radiation, UNSCEAR 2008 Report: Sources and Effects of Ionizing Radiation. Report to the General Assembly with scientific annexes A and B, 2010, United Nations, New York.
230. [230] Brenner, D.J., Curtis, R.E., Hall, E.J., Ron, E., Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 88:2 (2000), 398–406.
231. [231] Ron, E., Cancer risks from medical radiation. Health Phys. 85:1 (2003), 47–59.
232. [232] Stewart, A., Webb, J., Hewitt, D., A survey of childhood malignancies. Br. Med. J. 1:5086 (1958), 1495–1508.
233. [233] Wakeford, R., Childhood leukaemia following medical diagnostic exposure to ionizing radiation in utero or after birth. Radiat. Prot. Dosim. 132:2 (2008), 166–174.
234. [234] Boice, J.D. Jr., Preston, D., Davis, F.G., Monson, R.R., Frequent chest X-ray fluoroscopy and breast cancer incidence among tuberculosis patients in Massachusetts. Radiat. Res. 125:2 (1991), 214–222.
235. [235] Howe, G.R., McLaughlin, J., Breast cancer mortality between 1950 and 1987 after exposure to fractionated moderate-dose-rate ionizing radiation in the Canadian fluoroscopy cohort study and a comparison with breast cancer mortality in the atomic bomb survivors study. Radiat. Res. 145:6 (1996), 694–707.
236. [236] Doody, M.M., Lonstein, J.E., Stovall, M., Hacker, D.G., Luckyanov, N., Land, C.E., Breast cancer mortality after diagnostic radiography: findings from the U.S. Scoliosis Cohort Study. Spine (Phila Pa 1976) 25:16 (2000), 2052–2063.
237. [237] Berrington de González, A., Darby, S., Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. Lancet 363:9406 (2004), 345–351.
238. [238] Pearce, M.S., Salotti, J.A., Little, M.P., McHugh, K., Lee, C., Kim, K.P., et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet 380:9840 (2012), 499–505.
239. [239] Mathews, J.D., Forsythe, A.V., Brady, Z., Butler, M.W., Goergen, S.K., Byrnes, G.B., et al. Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians. BMJ, 346, 2013, f2360.